Timeline
Step into the IBD Timeline and embark on a journey through the chronological milestones, breakthroughs, and significant studies that have shaped the understanding and treatment of IBD. Explore the evolution of research, therapies, and key discoveries that have paved the way for advancements in IBD care.
Coming soon…
List with the upcoming studies
ACCURE
ACCURE-UK
COSTA
SEQUENCE
PROFILE
STATIC
IASO
REPREVIO
SOPRANO-CD
MEERKAT
SPICY
TITRATE
TRIBUTE
COMBINE
COMMET
TENOR
QUASAR
UNIFI Jr
DUMBO
PREdiCCt
IVEMEI
JUNIPER
SERENITY
NOR-DRUM B
COTTONWOOD
INTREPID
ELDERLUST
RESERVO
VERSUS CD
LOVE-UC
EXPLORER
EXPEDITION
AMBER 2
BIOSCOPE
PREVEDO
PROFUST
VERDICT
CD HOPE
DIETOMICS CD
GRAVITI
CONCLUDE
DUET UC
POWER
SEMI-VEG
PIONIR
MELODY
VALUE
OATS
CD-TDI
PROACTIVE
ADDapt
LIBERTY-UC
LIBERTY-CD
CD-TREAT
IBD-FITT
ACHILLES
LATTICE-UC
USTAP
DIVERSITY
YELLOWSTONE
and many more
2024
ASTIClite
Safety and efficacy of autologous haematopoietic stem-cell transplantation with low-dose cyclophosphamide mobilisation and reduced intensity conditioning versus standard of care in refractory Crohn’s disease (ASTIClite): an open-label, multicentre, randomised controlled trial
Albumin ASUC
Intravenous albumin infusion does not augment the response rate to a combination of exclusive enteral nutrition and intravenous steroids in acute severe ulcerative colitis: a randomized controlled trial
ARTEMIS-UC
Phase 2 Trial of Anti-TL1A Monoclonal Antibody Tulisokibart for Ulcerative Colitis
AZA+EEN postop
Azathioprine Plus Exclusive Enteral Nutrition Versus Azathioprine Monotherapy for the Prevention of Postoperative Recurrence in Patients with Crohn’s Disease: An Open-Label, Single-Centre, Randomized Controlled Trial
COCONUT WATER-UC
Coconut water vs placebo in active mild-moderate UC patients on standard medication
Cognitive behavioral therapy-ibd
The impact of group cognitive behavioral psychotherapy on disease severity and psychosocial functioning in patients with inflammatory bowel disease: a randomized controlled study
COMMAND & INSPIRE
ENTERPRET
A Randomized Controlled Trial of Vedolizumab Dose Optimization in Patients With Ulcerative Colitis Who Have Early Nonresponse
LIBERTY-UC/CD
Subcutaneous Infliximab (CT-P13 SC) as Maintenance Therapy for Inflammatory Bowel Disease: Two Randomized Phase 3 Trials
OPTIMISE
Clinical Trial: A Pragmatic Randomised Controlled Study to Assess the Effectiveness of Two Patient Management Strategies in Mild to Moderate Ulcerative Colitis—The OPTIMISE Study
See summary
PROFILE
A biomarker-stratified comparison of top-down versus accelerated step-up treatment strategies for patients with newly diagnosed Crohn’s disease (PROFILE): a multicentre, open-label randomised controlled trial
PREDICT-UC
Intensified versus standard dose infliximab induction therapy for steroid-refractory acute severe ulcerative colitis (PREDICT-UC): an open-label, multicentre, randomised controlled trial
PROTECT 1/2
Modified-Release Phosphatidylcholine (LT-02) for Ulcerative Colitis: Two Double-Blind, Randomized, Placebo-Controlled Trials
Reverse-engineered EEN
Reverse-engineered exclusive enteral nutrition in pediatric Crohn’s disease: A pilot trial
RNA oligonucleotide
Submucosal Injection of the RNA Oligonucleotide GUT-1 in Active Ulcerative Colitis Patients: A Randomized, Double– Blind, Placebo-Controlled Phase 2a Induction Trial
SEQUENCE
Risankizumab versus Ustekinumab for Moderate-to-Severe Crohn’s Disease
SPICY
Effect of mesenteric sparing or extended resection in primary ileocolic resection for Crohn’s disease on postoperative endoscopic recurrence (SPICY): an international, randomised controlled trial
Thiopurine withdrawal on VEDO
Effects of Thiopurine Withdrawal on Vedolizumab-Treated Patients With Ulcerative Colitis: a RandomizedControlled Trial
2024
2023
BERGAMOT
BETA-FRUCTANS
COMBINE
Curcumin-QingDai
DIVERGENCE 1
EARNEST
ELEVATE
EXPLORER
GALAXI-1
Phase 2 trial, guselkumab in Crohn’s disease efficacy and safety at week 48
LAG-3 depleting Ab
LADI
LUCENT 1 & 2
MCP-UC
Mediterranean diet
Olamkicept
ORCHID
OTC multivitamin/mineral supplement
Over-the-Counter Multivitamin and Mineral Supplement to Prevent Infections in IBD Patients
POPEYE
Ferric carboxymaltose vs Ferrous fumarate in Anemic children with IBD
QUASAR 2b
Guselkumab in Patients With Moderately to Severely Active Ulcerative Colitis: QUASAR Phase 2b Induction Study
RUN-CD
Ritlecitinib-brepocitinib
SPARE
SLRIPS
TACOS
The decider study
Allopurinol-thiopurine versus standard thiopurine in patients with IBD
U-EXCEL;U-EXCEED; U-ENDURE
U-ACHIEVE maintenance
VIBRATO
VEDOKIDS
Vagus nerve stimulation
VEGA
5ASA MMX kids
5ASA CD
2022
AAUC
ABX464-OBEFAZIMOD
ADVANCE & MOTIVATE
AID vs CFG -UC
Anti-Inflammatory Diet Prevents Subclinical Colonic Inflammation and Alters Metabolomic Profile of UC in Clinical Remission
See summary
AJM300
CDED-AD
The Crohn’s disease exclusion diet for induction and maintenance of remission in CD
See summary
COMBO-MESA
CRAFT-UC
FMT-AID
Faecal microbiota transplantation with anti-inflammatory diet (FMT-AID) in UC induction and maintenance
ENTERPRISE
ERIca
FORTIFY
GALAXI 1
HICKORY
HIBISCUS I&II
HUBBLE
LAUREL
LOTUS
Mirikizumab-ph2-CD
PIANO registry
PISA-II
Protdilat
Self-expandable metal stents vs endoscopic balloon dilation for the treatment of strictures in Crohn’s disease
PUCCINI
REMSWITCH
SERENE-CD
SERENE-UC
STARDUST
STOP-IT
SEAVUE
Spesolimab
SUSTAIN
Surgery and antiTNF perianal CD
Surgical closure, mainly with glue injection and anti-tumour necrosis factor α, in perianal CD
See summary
TISkids
TOUR
U-ACHIEVE & U-ACCOMPLISH
VISIBLE 2
VIP
5HTP-fatigue
2022
2021
CLARITY
DINE-CD
EEN in UC
ENVISION I
FUTURE
GARDENIA
HAYABUSA
Discontinuation of infliximab in patients with ulcerative colitis in remission (HAYABUSA): a multicentre, open-label, randomised controlled trial
IFX IV/SC
Low fat high fibre diet UC
Low-Fat, High-Fiber Diet Reduces Markers of Inflammation and Dysbiosis and Improves Quality of Life in UC
NOR-DRUM A
NOR-DRUM B
OASIS-OLE
PRECISION
RIVETING
SELECTION
STRIDENT
TOUCHSTONE-OLE
UNISTAR
TRUE NORTH
VOLTAIRE-CD
2020
AZA to avoid A-D-Ab
2º antiTNF +/- Azathioprine in IBD patients who had immune mediated LOR to first antiTNF
CELEST
CONCEIVE
CONDUCT
Low FODMAP-IBD
Low FODMAP trial on Symptoms, Fecal Microbiome, and Markers of Inflammation in Patients With Quiescent Inflammatory Bowel Disease
Mirikizumab-phase2 UC
OASIS
PIANO
PISA-I
PRASCO
PRESENCE
SCD diet ped-CD
Specific Carbohydrate Diet and Diet Modification as Induction Therapy for Pediatric CD
SUPREME-CD
STEPSTONE
TACRO/BECLO
Tacrolimus suppositories vs beclomethasone suppositories in proctitis
U-ACHIEVE
VISIBLE 1
I6T-MC-AMAC
2020
2019
Abrilumab
ADA-pouchitis
ANDANTE I & II
CDED+PEN
Crohn’s Disease Exclusion Diet Plus Partial Enteral Nutrition Induces Sustained Remission in a Randomized Controlled Trial
DIAMOND 2
FACES
LOVE-CD
PANTS
PAILOT
PLANET CD
UNIFI
VARSITY
VERSIFY
2018
ADMIRE-CD
ATICCA
BUDEFOAM
Budesonide-CD
INDIGO NATURALIS
IFX postop
MERIT-UC
OPERA
SECURE
TAILORIX
TEDDY
2018
2017
APPRECIA
Budesonide- CD Japan
Efficacy and Safety of Oral Budesonide in Patients with Active
Crohn’s Disease in Japan: A Multicenter, Double-Blind,
Randomized, Parallel-Group Phase 3 Study
CALM
Adalimumab +/- azathioprine tight control vs clincal management in CD
CANNABIDIOL-CD
Low-Dose Cannabidiol Is Safe but Not Effective in the Treatment for Crohn’s Disease, a Randomized Controlled Trial
CREOLE
EEN in CD
EXTEND
ENCORE-CD
FITZROY
GOLI kids
IRON IV/PO
Oral versus intravenous iron replacement therapy distinctly alters the gut microbiota and metabolome in patients with IBD
LIR!C
Multidonor FMT
MUPPIT
Once- Versus Twice-daily Mesalazine to Induce Remission in Paediatric Ulcerative Colitis: A Randomised Controlled Trial
NOR-SWITCH
CT-P13 or infliximab originator in immune mediated inflammatory diseases
PURSUIT-J
Efficacy and safety of golimumab 52-week maintenance therapy in Japanese patients with moderate to severely active ulcerative colitis: a phase 3, double-blind, randomized, placebo-controlled study-(PURSUIT-J study)
OCTAVE 1&2
Risankizumab ph2-cd
TOPIC TACRO
TURANDOT
TOFA-CD
Tofacitinib for induction and maintenance therapy of Crohn’s disease: results of two phase IIb randomised placebo-controlled trials
no-carrageenan diet UC
2016
ADMIRE-CD
Allogeneic adipose-derived mesenchymal stem cells (Cx601) in perianal CD
ART
Australian vs low FODMAP diet
Consistent Prebiotic Effect on Gut Microbiota With Altered FODMAP Intake in Patients with CD
CONSTRUCT
COLLECT
DIAMOND
ELDELUMAB-UC
Eldelumab [Anti-IP-10] Induction Therapy for Ulcerative Colitis: A Randomised, Placebo-Controlled, Phase 2b Study
IM-UNITI
Ustekinumab in CD safety
IGG4-exclusion diet
METEOR
MOMENTUM
Ulcerative Colitis Remission Status After Induction With Mesalazine Predicts Maintenance Outcomes: theMOMENTUM Trial
TOUCHSTONE
TOPPIC
PREVENT
UNITI I&II
2016
2015
BUDEFOAM
BETA
Beclomethasone Dipropionate and Prednisone in the Treatment of Active UC
Curcumin+5ASA
Curcumin in Combination With Mesalamine Induces Remission in Patients With Mild-to-Moderate Ulcerative Colitis in a Randomized Controlled Trial
MTX kids SC/PO
MSC perianal disease
Allogeneic Bone Marrow–Derived Mesenchymal Stromal Cells in Perianal Fistulas in CD
See summary
Mongersen -CD
Mongersen, an Oral SMAD7 Antisense Oligonucleotide, and Crohn’s Disease
POCER
PURSUIT-IV
REACT
STRIDE
Thalidomide kids UC
TPMT adjustment
Identification of Patients With Variants in TPMT and Dose Reduction Reduces Hematologic Events During Thiopurine Treatment of Inflammatory Bowel Disease
TAXIT
VSL3 postop
Vercirnon-CD
Randomised clinical trial: vercirnon, an oral CCR9 antagonist,vs. placebo as induction therapy in active Crohn’s disease
2014
ADA in UC Japan
ADAFI
BUDESONIDE-CD DOSES
Once versus three times daily dosing of oral budesonide for active Crohn’s disease: A double-blind, double-dummy, randomised trial
COMMIT
ETROlizumab-UC
Etrolizumab as induction therapy for ulcerative colitis: a randomised, controlled, phase 2 trial
FHAST-1
AST-120 (Spherical Carbon Adsorbent) in the Treatment of Perianal Fistulae in Mild-to-Moderate CD
See summary
GEMINI III
GROWTH-CD
IFX/ADA postop
Mindfulness-UC
A Randomized Controlled Trial of Mindfulness-Based Stress Reduction to Prevent Flare-Up in Patients with Inactive Ulcerative Colitis
PURSUIT-M
PURSUIT-SC
UC-SUCCESS
5ASA dose kids
2014
2013
Apheresis-CD
A randomised, double-blind, sham-controlled study of granulocyte/monocyte apheresis for moderate to severe Crohn’s disease
See summary
AZA/ IFX postop
AZA +/- METRO postop
AZTEC
Budesonide-CD
Cipro postop
Cow Milk Protein exclusion diet ped-UC
GEMINI I
GEMINI II
IFX kids
MOTUS
MUSIC
Naltrexone-pedCD
Safety and Tolerability of Low-dose Naltrexone Therapy in Children With Moderate to Severe Crohn’s Disease A Pilot Study
RAPID
Thalidomide kids CD
5ASA sup
ABATACEPT- CD/UC
APHERESIS-CD
A randomised, double-blind, sham-controlled study of granulocyte/monocyte apheresis for moderate to severe Crohn’s disease
ADA in Japanese-CD
ADA/AZA/5ASA postop
Basiliximab-UC
Basiliximab does not increase efficacy of corticosteroids in patients with steroid-refractory ulcerative colitis
CERTIFI
CORE I
CYSIF
EXTEND
IMAgINE 1
IFX postop
PODIUM
RIFAXIMIN-CD
Rifaximin-Extended Intestinal Release Induces Remission in Patients With Moderately Active Crohn’s Disease
SECUKINUMAB
SWITCH
TACRO UC
STORI
ULTRA II
2012
2011
FOS-CD
L-Carnitine in UC
Randomised clinical trial: the efficacy and safety of propionyl-l-carnitine therapy in patients with ulcerative colitis receiving stable oral treatment
ULTRA I
WELCOME
5ASA doses- UC
Randomised clinical trial: a comparative dose-finding study of three arms of dual release mesalazine for maintaining remission in ulcerative colitis
5ASA vs budesonide-UC
5ASA vs budesonide-CD
2010
ADHERE
CHOICE
The CHOICE trial: adalimumab demonstrates safety, fistula healing, improved quality of life and increased work productivity in patients with Crohn’s disease who failed prior infliximab therapy
Fibrin glue perianal CD
IgG Food antigen CD
Metronidazole ointment perianal CD
PRECiSE III
PRECiSE 4
SONIC
5ASA vs AZA postop
2010
2009
AZA/5ASA postop
IFX postop
5ASA-MMX Asacol
2008
AST-120 perianal CD
Oral Spherical Adsorptive Carbon for the Treatment of Intractable Anal Fistulas in CD
Balsalazide
Clarithromycin in CD
randomized study of clarithromycin versus placebo in active Crohn’s disease
EPIC 1 & 2
Omega-3 Free Fatty Acids for the Maintenance of Remission in Crohn Disease
Everolimus vs AZA
METRO+/- AZA postop
SUTD
2008
2007
Antibiotic combo in CD
Two-Year Combination Antibiotic Therapy With Clarithromycin, Rifabutin, and Clofazimine for Crohn’s Disease
ASCEND I
Mesalazine high/low dose in UC
CLASSIC II
CHARM
DIET in CD
GAIN
Natalizumab+IFX
Safety and Tolerability of Concurrent Natalizumab Treatment for Patients with Crohn’s Disease Not in Remission While Receiving Infliximab
PRECiSE II
PRECiSE I
Probiotics postop
REACH
synbiotics postop
topical tacrolimus in PCD
2006
CLASSIC I
Half elemental diet CD
Effectiveness of an ‘half elemental diet’ as maintenance therapy for CD
See summary
Polymeric diet vs steroids
Polymeric Diet Alone Versus Corticosteroids in the Treatment of Active Pediatric Crohn’s Disease: A Randomized Controlle Open-Label Trial
PEN vs TEN diet CD
probiotics postop
TACRO UC
TREAT
5ASA-AZA
2006
2005
ACT 1&2
Budesonide longterm-CD
ENACT-1 & 2
LGG kids
Microparticle diet CD
Lack of efficacy of a reduced microparticle diet in a multi-centred trial of patients with active CD
Ornidazol postop
PINCE
2004
Aloe vera in UC
ACCENT II
BUDE/PRED kids
IFX +/- ciprofloxacin perianal cd
5ASA/AZA postop
5ASA/6MP postop
2004
2003
CYCLO 2/4
EGF enema
Natalizumab
Oral tacrolimus fistulizing CD
Steroids & Immunogenicity
5ASA postop
2002
ACCENT I
Beclomethasone
Budesonide-CD
Lactobacillus postop
2002
2001
CICLO vs STEROIDS
5ASA foam enema
2000
IL-10 - CD phase 2
Recombinant human interleukin 10 in the treatment of patients with mild to moderately active Crohn’s disease
IL-10 - CD phase 3
Safety and efficacy of recombinant human interleukin 10 in chronic active Crohn’s disease
MCP kids
MCP-MTX-5ASA
MTX-CD
5ASA postop
5ASA sup
2000
1999
IFX-CD
IFX-fistulising CD
Plantago ovata
1998
Budesonide vs mesalazine-cd
1998
1997
IFX-CD
1996
Methotrexate- UC
Omega3 & Low carbohydrate diet CD
Omega-3 Fatty Acids and Low Carbohydrate Diet for Maintenance of Remission in CD
See summary
1996
1995
AZA-CD
Elimination diet-UC
Elimination diet in the management of patients with ulcerative colitis
See summary
IFX-cA2
MTX- CD
METRO postop
1994
Budesonide -CD
Hyperbaric oxygen-perianal CD
Hyperbaric oxygen in perianal CD
Oral 5ASA -CD
Oral 5ASA in ileocolonic and colonic CD
1994
1993
Mesalamine CD
Mesalamine for CD a 16-week trial
Prednisone +/- Azathioprine- CD
1992
1992
1991
fecal stream postop
Metronidazole-CD
Double blind, placebo controlled trial of metronidazole
in Crohn’s disease
1990
Smoking & postop recurrence
Slow release 5ASA in CD
Slow-Release 5-Amino-Salicylic Acid (Pentasa®) for the Treatment of Active Crohn’s Disease
1990
1987
Incision +/- fistulotomy pCD
5ASA-CD
1986
1986
1985
Diet trial CD
Unrefined carbohydrate fibre rich diet vs diet with exclusion of specific foods in the maintenance of remission in CD
See summary
fecal stream postop
EEN in CD
Controlled trial comparing prednisolone with an elemental diet plus non-absorbable antibiotics in active Crohn’s disease
Low residue diet CD
1984
sulfasalazine & 6-methylprednisolone in CD
European Cooperative Crohn’s Disease Study (ECCDS): results of drug treatment
See summary
4ASA enemas
1984
1983
Supplemented oral nutrition CD
1982
TRANEXAMIC
1982
1981
5ASA enema
1980
Mercaptopurine-CD
Sulphapyridine vs 5-ASA
1980
1979
Pred- AZA-Sulphapyridine in CD
1978
Prednisone single/multiple doses UC
Steroids-CD
1978
1977
Metronidazol UC
1974
Azathioprine UC
Azathioprine CD
Salazopyrin CD
1974
1973
Sulphasalazine UC
1972
1972
1971
Azathioprine-CD
Azathioprine-CD II
1968
1968
1967
1966
1966
1965
Prednisone maintenance UC
Sulphasalazine maintenance UC
Various diets UC
A Controlled Therapeutic Trial of Various Diets in Ulcerative Colitis
See summary
1964
1964
1963
1962
Prednisone in UC
Steroids vs sulphasalazine in UC
Sulphasalazine in UC
Steroid sup UC proctitis
1962
1961
1960
corticosteroids in uc
oral steroids vs topical vs Salazopyrin
Prednisone, Salazopyrin and Topical Hydrocortisone Hemisuccinate in UC
1960
1959
Cortisone and corticotrophin in uc
1958
Topical Hydrocortisone
Topical Hydrocortisone Hemisuccinate Sodium for induction of remission UC
Topical Hydrocortisone II
Topical Hydrocortisone Hemisuccinate Sodium for induction of remission UC
1958
1955
cortisone in asuc
Any suggestions?
If you have any suggestion of trials or studies to add, changes or corrections of any error, feel free to write me here
Illustrations by Cristina Gros Content creator and development Beatriz Gros
